• ThromboGenics Inc.

    ThromboGenics Inc. says the FDA has approved its pre-diluted formulation of ocriplasmin (Jetrea) for treatment of symptomatic vitreomacular adhesion (VMA).

    The original form of ocriplasmin requires dilution prior to intravitreal administration. The new formulation requires no dilution. ThromboGenics expects the new formulation will be available in the first half of 2017.